Source item
Open original source ↗2 segments
Segment 1 · characters 0–23 · Original segment ↗
Segment 2 · characters 25–123 · Original segment ↗
Quoted context
These are the quoted author’s words.
🥐RUMBS 👇 With $APLS being taken out overnight for a $ñ150% premium… Soleno Therapeutics $SLNO should be next… They’ve already penetrated >1.25k of the 10k patients in the US & should 2x that in the next year… That would be $6-8/share in FCF!! And W/ $500 mil in 💰, that’san enterprise value of only $23/share. The ultimate annual opportunity is 5k-7k patients 👇. & the ONLY competitor was a competing drug from Aardvark [$AARD] which was halted for safety…leaving $SLNO as the ONLY 💊 option. It’s just a ❓ of how quickly theyre going to ramp to $16/share in FCF. It may be the cheapest stock in the whole market w/ M&A in the sector 🔥 up… (*Not investment advice- Donyour own research…I own the stock 🤑)
jam_croissant ↗